TREMFYA Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving TREMFYA Growth

1. Strong and durable clinical efficacy across indications

• In Phase III DISCOVER trials (PsA):
• 40% of patients achieved minimal disease activity (MDA) at ~2 years
• Up to 83% resolution of dactylitis and 70% enthesitis resolution by week 100
• In plaque psoriasis:
• ~83% of patients maintained PASI 90 (near complete skin clearance) at 3 years

2. Disease-modifying potential (structural damage inhibition)

• TREMFYA demonstrated:
• Low radiographic progression over 2 years in PsA patients
• It is among the first IL-23 inhibitors showing inhibition of joint structural damage progression

3. Favorable safety profile enabling long-term use

• Across Phase II/III trials:
• Low rates of serious adverse events and opportunistic infections
• Safety profile consistent across psoriasis and PsA populations

4. Broad label expansion (multi-indication growth)

TREMFYA is approved for:

• Moderate-to-severe plaque psoriasis
• Psoriatic arthritis
• Also being explored in - Inflammatory bowel disease (IBD) (e.g., Crohn's disease, ulcerative colitis - per company pipelines)

5. Differentiated mechanism (IL-23 p19 inhibition)

• TREMFYA selectively inhibits IL-23 (p19 subunit), a key cytokine in inflammatory pathways
• Compared with older TNF inhibitors:
• More targeted immune modulation
• Better skin clearance outcomes (PASI 90/100 rates)

6. Strong real-world and quality-of-life benefits

• Clinical and real-world studies show:
• Improvements in pain, fatigue, and work productivity
• Sustained improvements in health-related quality of life (HRQoL)

TREMFYA Recent Developments

In February 2026, Johnson & Johnson announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA (Guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis (UC). These data are among the 30 company-sponsored abstracts being presented at the European Crohn's and Colitis Organisation (ECCO) 2026 conference.

"TREMFYA Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of TREMFYA for approved indication like Crohn's disease, Erythrodermic psoriasis, Juvenile rheumatoid arthritis, Palmoplantar pustulosis, Plaque psoriasis, Psoriatic arthritis, and Pustular psoriasis; as well as potential indication like Hidradenitis suppurativa and Systemic scleroderma in the 7MM. A detailed picture of TREMFYA's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the TREMFYA for approved and potential indications. The TREMFYA market report provides insights about TREMFYA's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current TREMFYA performance, future market assessments inclusive of the TREMFYA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of TREMFYA sales forecasts, along with factors driving its market.

TREMFYA Drug Summary

TREMFYA (Guselkumab) is a human monoclonal antibody developed by Johnson & Johnson that selectively targets the p19 subunit of interleukin-23 (IL-23), a key cytokine involved in inflammatory and immune pathways. By inhibiting IL-23 signaling, TREMFYA reduces the activation and proliferation of pro-inflammatory T cells, thereby decreasing the release of downstream cytokines that drive chronic inflammation. It is approved for the treatment of moderate-to-severe Plaque Psoriasis and active Psoriatic Arthritis, where it has demonstrated high rates of skin clearance and sustained clinical response in patients. Administered via subcutaneous injection, TREMFYA offers a targeted immunomodulatory approach with a favorable safety profile and durable efficacy, positioning it as a leading biologic therapy in the management of IL-23-mediated inflammatory diseases. The report provides TREMFYA's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the TREMFYA Market Report

The report provides insights into:

• A comprehensive product overview including the TREMFYA MoA, description, dosage and administration, research and development activities in approved indications like Crohn's disease, Erythrodermic psoriasis, Juvenile rheumatoid arthritis, Palmoplantar pustulosis, Plaque psoriasis, Psoriatic arthritis, and Pustular psoriasis; as well as potential indication like Hidradenitis suppurativa and Systemic scleroderma.
• Elaborated details on TREMFYA regulatory milestones and other development activities have been provided in TREMFYA market report.
• The report also highlights TREMFYA's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The TREMFYA market report also covers the patents information, generic entry and impact on cost cut.
• The TREMFYA market report contains current and forecasted TREMFYA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The TREMFYA market report also features the SWOT analysis with analyst views for TREMFYA in approved and potential indications.

Methodology:

The TREMFYA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TREMFYA Analytical Perspective by DelveInsight

• In-depth TREMFYA Market Assessment

This TREMFYA sales market forecast report provides a detailed market assessment of TREMFYA for approved indication like Crohn's disease, Erythrodermic psoriasis, Juvenile rheumatoid arthritis, Palmoplantar pustulosis, Plaque psoriasis, Psoriatic arthritis, and Pustular psoriasis; as well as potential indication like Hidradenitis suppurativa and Systemic scleroderma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted TREMFYA sales data uptil 2034.

• TREMFYA Clinical Assessment

The TREMFYA market report provides the clinical trials information of TREMFYA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

TREMFYA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

TREMFYA Market Potential & Revenue Forecast

• Projected market size for the TREMFYA and its key indications
• Estimated TREMFYA sales potential (TREMFYA peak sales forecasts)
• TREMFYA Pricing strategies and reimbursement landscape

TREMFYA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• TREMFYA Market positioning compared to existing treatments
• TREMFYA Strengths & weaknesses relative to competitors

TREMFYA Regulatory & Commercial Milestones

• TREMFYA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

TREMFYA Clinical Differentiation

• TREMFYA Efficacy & safety advantages over existing drugs
• TREMFYA Unique selling points

TREMFYA Market Report Highlights

• In the coming years, the TREMFYA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The TREMFYA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TREMFYA's dominance.
• Other emerging products for Crohn's disease, Erythrodermic psoriasis, Juvenile rheumatoid arthritis, Palmoplantar pustulosis, Plaque psoriasis, Psoriatic arthritis, and Pustular psoriasis; as well as potential indication like Hidradenitis suppurativa and Systemic scleroderma are expected to give tough market competition to TREMFYA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TREMFYA in approved and potential indications.
• Analyse TREMFYA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted TREMFYA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of TREMFYA in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of TREMFYA? How strong is TREMFYA's clinical and commercial performance?
• What is TREMFYA's clinical trial status in each individual indications such as Crohn's disease, Erythrodermic psoriasis, Juvenile rheumatoid arthritis, Palmoplantar pustulosis, Plaque psoriasis, Psoriatic arthritis, and Pustular psoriasis; as well as potential indication like Hidradenitis suppurativa and Systemic scleroderma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TREMFYA Manufacturers?
• What are the key designations that have been granted to TREMFYA for approved and potential indications? How are they going to impact TREMFYA's penetration in various geographies?
• What is the current and forecasted TREMFYA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of TREMFYA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to TREMFYA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is TREMFYA? What is the duration of therapy and what are the geographical variations in cost per patient?